Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.050 Biomarker group BEFREE Targeting the tumor-restricted, glycosylation-dependent Siglec-9 axis may unleash this intratumoral T-cell subset, while confining T-cell activation to the tumor microenvironment. 30988027 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.010 AlteredExpression disease BEFREE Changes in Siglec-9 sialoglycan ligand expression on vascular endothelial cells may be a natural response to the initial steps of atherosclerosis and might be a potential target to regulate inflammation in diabetic angiopathy. 30471282 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.010 AlteredExpression disease BEFREE Changes in Siglec-9 sialoglycan ligand expression on vascular endothelial cells may be a natural response to the initial steps of atherosclerosis and might be a potential target to regulate inflammation in diabetic angiopathy. 30471282 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.010 Biomarker group BEFREE Targeting Siglec-7 and Siglec-9, or the sialic acid coated tumor cell surface is therefore being investigated as a novel therapeutic approach to enhance the NK cell response against cancer. 31143186 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.010 Biomarker disease BEFREE Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. 31489145 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.010 AlteredExpression disease BEFREE However, here, we report that the majority of intratumoral, but not peripheral blood, cytotoxic CD8<sup>+</sup> T cells expressed Siglec-9 in melanoma. 30988027 2019
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma 		0.010 Biomarker disease BEFREE Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. 31489145 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.010 Biomarker disease BEFREE Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. 31489145 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.010 Biomarker group BEFREE Targeting Siglec-7 and Siglec-9, or the sialic acid coated tumor cell surface is therefore being investigated as a novel therapeutic approach to enhance the NK cell response against cancer. 31143186 2019
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.010 Biomarker disease BEFREE Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. 31489145 2019
CUI: C1305855
Disease: Body mass index
Body mass index 		0.100 GeneticVariation phenotype GWASCAT Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. 29273807 2018
CUI: C2985280
Disease: Blood Protein Measurement
Blood Protein Measurement 		0.100 GeneticVariation phenotype GWASCAT Genomic atlas of the human plasma proteome. 29875488 2018
CUI: C0004096
Disease: Asthma
Asthma 		0.010 Biomarker disease BEFREE Targeting Neutrophils in Severe Asthma via Siglec-9. 29306942 2018
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.010 AlteredExpression disease BEFREE T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer. 30130255 2018
CUI: C0008055
Disease: Chikungunya Fever
Chikungunya Fever 		0.010 AlteredExpression disease BEFREE Expression of Siglec-9 on monocytes; which can modulate oxidative stress is studied along with intracellular reactive oxygen species (ROS), cellular lipid and protein damage markers in chikungunya patients with/without persisting polyarthralgia along with healthy controls. 29898618 2018
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.010 AlteredExpression disease BEFREE T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer. 30130255 2018
CUI: C0018378
Disease: Guillain-Barre Syndrome
Guillain-Barre Syndrome 		0.010 Biomarker disease BEFREE Transgenic mice expressing the soluble form of Siglec-9 showed significant resistance against GBS infection and remarkable suppression of MUC1 expressing tumor proliferation. 29342882 2018
CUI: C0024115
Disease: Lung diseases
Lung diseases 		0.010 Biomarker group BEFREE Given that neutrophils are probably a major culprit in the generation and perpetuation of inflammation, targeting Siglec-9 could be beneficial for the treatment of severe asthma, chronic obstructive pulmonary disease, and related pulmonary disorders characteristic of neutrophilia. 29306942 2018
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block 		0.010 Biomarker disease BEFREE Neutralization of Siglec-9 restored cytokine synthesis and degranulation of NK cells from CHB patients. 29899741 2018
CUI: C0162296
Disease: Polyarthralgia
Polyarthralgia 		0.010 AlteredExpression disease BEFREE Expression of Siglec-9 on monocytes; which can modulate oxidative stress is studied along with intracellular reactive oxygen species (ROS), cellular lipid and protein damage markers in chikungunya patients with/without persisting polyarthralgia along with healthy controls. 29898618 2018
CUI: C0524909
Disease: Hepatitis B, Chronic
Hepatitis B, Chronic 		0.010 Biomarker disease BEFREE Here, we studied the potential regulatory roles of NK Siglec-9 in the pathogenesis of chronic hepatitis B (CHB) infection. 29899741 2018
CUI: C2020625
Disease: Group B Streptococcal Infection
Group B Streptococcal Infection 		0.010 Biomarker disease BEFREE Transgenic mice expressing the soluble form of Siglec-9 showed significant resistance against GBS infection and remarkable suppression of MUC1 expressing tumor proliferation. 29342882 2018
CUI: C3665444
Disease: Neutrophilia (disorder)
Neutrophilia (disorder) 		0.010 Biomarker disease BEFREE Given that neutrophils are probably a major culprit in the generation and perpetuation of inflammation, targeting Siglec-9 could be beneficial for the treatment of severe asthma, chronic obstructive pulmonary disease, and related pulmonary disorders characteristic of neutrophilia. 29306942 2018
CUI: C4083008
Disease: Guillain-Barre Syndrome, Familial
Guillain-Barre Syndrome, Familial 		0.010 Biomarker disease BEFREE Transgenic mice expressing the soluble form of Siglec-9 showed significant resistance against GBS infection and remarkable suppression of MUC1 expressing tumor proliferation. 29342882 2018
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.010 AlteredExpression disease BEFREE T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer. 30130255 2018